AlphAIAlphAI — Financial news for AI agents
insidermonkey.comSEP 282 min read$NBTX

Can J&J’s Partnership Drive More Upside for Nanobiotix?

Guggenheim initiated coverage of Nanobiotix (NBTX) with a Buy rating and $64 price target, focusing on its JNJ-1900 partnership with Johnson & Johnson (JNJ). The NANORAY-312 Phase 3 trial, evaluating JNJ-1900 in head and neck cancer, is expected to report final data in 2027. Guggenheim sees high odds of success, but the trial remains a key risk.

Original reporting
insidermonkey.com
Published Sep 28, 2026, 7:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Can J&J’s Partnership Drive More Upside for Nanobiotix? — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$NBTXBullishMed
01

Why it matters

Analyst initiation and a $64 target could attract new capital, but the key catalyst is not expected until 2027.

02

Market read

The article provides fresh analyst coverage and a price target, offering a modest trading cue for biotech investors.

03

What to watch

Potential milestone payments and regulatory risks could affect cash flow before any approval.

Relevance 6/10Novelty 6/10Timing: immediate

Background

Guggenheim's new coverage of Nanobiotix follows a 2023 licensing deal with Johnson & Johnson for the radioenhancer JNJ‑1900.

Company-level read

Ticker impact

$NBTXBullishMedium confidence
Context

Guggenheim initiated coverage of Nanobiotix with a Buy rating and a $64 price target, highlighting the J&J partnership and the upcoming Phase 3 readout.

Expected impact

likely upward pressure as the market prices in the new buy rating and price target

Evidence & confidence

Coverage and a $64 target represent a fresh bullish thesis, but the catalyst is years away, limiting immediate impact.

Market effects

Sector

May boost interest in radiotherapy‑enhancer biotech sector and other J&J partnered programs.

Regional

Primarily U.S. biotech investors; limited broader market effect.

Global

Modest, confined to biotech and oncology investors worldwide.

Counterpoint

What could challenge this read

The long timeline to data and reliance on a single partner make the thesis risky; investors may stay cautious.

Key entities

  • company
    Nanobiotix S.A.

    Biotech firm developing JNJ‑1900 radioenhancer.

  • company
    Johnson & Johnson

    Global sponsor and partner for the Phase 3 trial.

Read at source← All news

Related articles

OCT 24
$NBTXHighAI 8/10

A 24-person study of treatment-resistant melanoma reported median survival of 17.8 months.

Nanobiotix (Euronext: NANO, NASDAQ: NBTX) presented Phase 1 study results showing 41.7% ORR and 17.8-month median survival in 24 advanced melanoma patients treated with JNJ-1900 (NBTXR3) and immunotherapy. The treatment demonstrated an acceptable safety profile and potential immune activation, warranting further trials. Data were shared at the 2026 ESMO Congress.

stocktitan.net2 min
SEP 24
$NBTXHigh

Nanobiotix S.A. (NBTX): Financial results for H1 2026

Nanobiotix S.A. (NBTX) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 NANOBIOTIX Provides First Half 2026 Operational and Financial Update Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoreg

SEC EDGAR 6-K3 min
MAY 26
$NBTXHighAI 9/10

NANOBIOTIX Announces Closing of Global Offering

Nanobiotix said it has closed its global offering, including the underwriters’ option for additional shares/ADSs. After full option exercise, it issued 2,218,467 ordinary shares (225,373 ADSs plus 33,805 additional ADSs) and 345,099 pre-funded warrants, raising about $100 million (€86.1 million) gross. Net proceeds will fund JNJ-1900 (<10%), Nanoprimer (50–60%), and general purposes (30–40%).

manilatimes.net2 min
OCT 24
$JNJHighAI 8/10

Johnson & Johnson announces ERLEADA® (apalutamide) treatment bef

Johnson & Johnson (JNJ) reported that a new study of its ERLEADA® (apalutamide) treatment, combined with androgen deprivation therapy (ADT), reduced the risk of recurrence or death by 62% in high-risk prostate cancer patients compared to surgery alone. The study also showed a 51% lower risk of metastasis or death. Results were presented at the ESMO Congress 2026.

gurufocus.com2 min
OCT 24
$AAPLLow

Apple's $2,000 iPhone Duo Hits Stores Worldwide as Rationed Sales Shrink Lines and Reviewers Urge Caution

Apple's iPhone Duo, priced at $2,000, launched globally with strong demand but limited supply. Apple rationed sales, avoiding long lines. Early reviews praise its design but note drawbacks like missing features. Apple aims to compete in the foldable phone market, dominated by Samsung and Huawei. Analysts expect Apple to capture a significant market share by 2027. The iPhone Duo is Apple's first major product under new CEO John Ternus.

ibtimes.com.au3 min